PT  - JOURNAL ARTICLE
AU  - He, Yan
AU  - Zhou, Xuzhao
AU  - Xu, Tao
AU  - Wu, Zhaofa
AU  - Guo, Wei
AU  - Xu, Xi
AU  - Liu, Yuntao
AU  - Zhang, Yi
AU  - Shang, Huiping
AU  - Yao, Zhimo
AU  - Li, Zewen
AU  - Li, Zhihui
AU  - Feng, Tao
AU  - Zhang, Shaomin
AU  - Cunha, Rodrigo A.
AU  - Huang, Zhili
AU  - Li, Yulong
AU  - Cai, Xiaohong
AU  - Qu, Jia
AU  - Chen, Jiang-Fan
TI  - 40 Hz Light Flickering Promotes Sleep through Cortical Adenosine Signaling
AID  - 10.1101/2023.10.07.23296695
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2023.10.07.23296695
4099  - http://medrxiv.org/content/early/2023/10/09/2023.10.07.23296695.short
4100  - http://medrxiv.org/content/early/2023/10/09/2023.10.07.23296695.full
AB  - Flickering light stimulation has emerged as a promising non-invasive neuromodulation strategy to alleviate neuropsychiatric disorders. However, the lack of a neurochemical underpinning has hampered its therapeutic development. Here, we demonstrate that light flickering triggered an immediate and sustained increase (up to 3 hours after flickering) in extracellular adenosine levels in the primary visual cortex and other brain regions, as a function of light frequency, intensity, and wavelength, with maximal effects observed at 40 Hz frequency. We discovered cortical (glutamatergic and GABAergic) neurons, rather than astrocytes, as the cellular source, and intracellular adenosine generation from calcium influx-triggered, AMPK- associated energy metabolism pathways (but not SAM-transmethylation or salvage purine pathways) and adenosine efflux mediated by equilibrative nucleoside transporter-2 (ENT2) as the molecular pathway responsible for extracellular adenosine generation. Importantly, 40 Hz light flickering for 30 min enhanced sleep in mice in a frequency-dependent manner. This somnogenic effect was absent in mice lacking ENT2 but replicated by administering adenosine to the visual cortex. Brief 40 Hz light flickering also promoted sleep in children with insomnia by decreasing sleep onset latency, increasing total sleep time, and reducing waking after sleep onset. Collectively, our findings establish adenosine signaling via ENT2 as the neurochemical basis for 40 Hz flickering-induced sleep and unravel a novel and non-invasive treatment for insomnia, a condition that affects 20% of the world population.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialChiCTR2300070938Funding StatementThis work was supported by the Science & Technology Initiative STI2030-Major Projects (Grant #2021ZD0203400 to J.-F.C.; 2022ZD0208300 to Z.W.), the National Natural Science Foundation of China (Grant #82151308 to J.-F.C.; 82101556 to X.Z.; 31970948 and 31600859 to W.G.; 81971031 to Z.L; 818700073 to X.H.C.; 81971064 to Y.Z.), the Research Fund for International Senior Scientists (Grant #82150710558 to J.-F.C), Start-up Fund (Grant #OJQDSP2022007 to J.-F.C.) from the Oujiang Laboratory (Zhejiang Lab for Regenerative Medicine, Vision and Brain Health), Program Project from the State Key Laboratory of Ophthalmology, Optometry and Vision Science, Wenzhou Medical University (Grant #J01- 20190101 to J.-F.C), Key Research Project (Grant #2023C03079 to J.-F.C) from Zhejiang Provincial Administration of Science & Technology, and the Natural Science Foundation of Zhejiang Province of China grant (Grant #LQ22H090013 to X.Z).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee/IRB of Eye Hospital of Wenzhou Medical University gave ethical approval for this work I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors